株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

統合失調症に伴う認知障害 (CIAS):パイプライン製品の分析 (2015年下半期)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 255980
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
統合失調症に伴う認知障害 (CIAS):パイプライン製品の分析 (2015年下半期) Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017
出版日: 2017年07月11日 ページ情報: 英文 104 Pages
概要

統合失調症の患者の場合、認知機能に軽度〜重度の障害が見られます。主な症状として、実行機能の弱さや、集中力を維持の難しさ、ワーキングメモリ (作業記憶) に関する問題などが挙げられます。素因となる要素として、家族歴や年齢、自己免疫疾患などが挙げられます。主な治療法として、抗精神病薬の投与などがあります。

当レポートでは、世界各国での統合失調症に伴う認知機能障害 (以下CIAS) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査した結果をお届けします。

目次

イントロダクション

  • 分析範囲

CIAS (統合失調症に伴う認知障害) の概要

治療薬の開発

  • CIAS向けパイプライン製品:概要
  • CIAS向けパイプライン製品:比較分析

各企業で開発中のCIAS治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

CIAS治療薬:開発中の製品の一覧 (企業別)

CIAS治療薬の開発に従事している企業

  • AbbVie Inc.
  • Amarantus Bioscience Holdings, Inc.
  • アステラス製薬
  • Avineuro Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Iproteos S.L.
  • Mnemosyne Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • Pfizer Inc.
  • Saniona AB
  • Siena Biotech S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • Sunovion Pharmaceuticals Inc. 36
  • 武田薬品工業
  • Upsher-Smith Laboratories, Inc.
  • Vanda Pharmaceuticals Inc.

CIAS:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • A-431404
    • 製品概要
    • 作用機序 (MoA)
    • 研究開発 (R&D) の進展状況
  • AN-761
  • AQW-051
  • ASP-4345
  • ASP-5736
  • AUT-1
  • AUT-6
  • AUT-9
  • AVL-3288
  • AVN-211
  • DSP-3748
  • エルトプラジン
  • 塩酸エンセニクリン
  • erteberel
  • IC-041
  • IPR-001
  • IPR-088
  • IPR-19
  • ITI-214
  • LUAF-64280
  • NSI-189
  • PF-04958242
  • PNU-120596
  • ロフルミラスト
  • SEN-15924
  • SKL-15508
  • SKL-A4R
  • 中枢神経系 (CNS) 向けアセチルコリン受容体サブユニットα-7作動用小分子
  • CIAS向け小分子
  • CIAS向けドーパミンD1受容体作動用小分子
  • CIAS向けNMDA2B作動用小分子
  • TAK-058
  • TAK-915

CIAS治療薬:最新の薬剤プロファイル

CIAS治療薬:開発が休止状態の製品

CIAS治療薬:開発が中止された製品

CIAS関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース (全6件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9504IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 12, 16 and 2 respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
    • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Amarantus Bioscience Holdings Inc
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Coronis NeuroSciences Ltd
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • H. Lundbeck A/S
    • Heptares Therapeutics Ltd
    • Intra-Cellular Therapies Inc
    • Iproteos SL
    • Luc Therapeutics Inc
    • Neuralstem Inc
    • Pfizer Inc
    • Sage Therapeutics Inc
    • Saniona AB
    • SK Biopharmaceuticals Co Ltd
    • Spherium Biomed SL
    • Suven Life Sciences Ltd
    • Takeda Pharmaceutical Company Ltd
    • Vanda Pharmaceuticals Inc
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
    • A-431404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQW-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-4345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basmisanil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-955829 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • davunetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltoprazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erteberel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-9936 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPR-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2814617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUAF-64280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-03463275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04958242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roflumilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGE-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKLA-4R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-14040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVND-4010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVNG-3031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-058 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0467154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant
      • Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
      • Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
      • Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top